CoronaryAtlas logo
CoronaryAtlas
triglyceride
Pathway / Lipid retention & oxidation

triglyceride

metabolite

Elevated triglycerides reflect accumulation of atherogenic lipoproteins in the intima, driving oxidative lipid modification and atherosclerotic plaque formation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleComponent of atherogenic lipid profile; triglyceride-rich lipoprotein retains in subendothelium.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
53
A — assay feasibility
42
E — evidence strength
72
T1DI (composite)
17
Specificity differential (R−C)+13.4
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 1
Coverage: 5/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 11 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(7)

Clinical trials(1)